¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16
±³À°ÀÏÀÚ : 2018-11-16
±³À°Àå¼Ò : °­¸ª¾¾¸¶Å©È£ÅÚ ¾Æ»êÆ®¸®¿ò  
±³À°ÁÖÁ¦ : Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  
À̸ÞÀÏ : webmaster@rheum.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °­¿øµµ
±³À°½Ã°£ : 11 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í : ȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 80,000¿øȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 40,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 80,000¿ø, ÇöÀåµî·Ï 100,000¿øºñȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:00~09:30 Validation of FRAX for osteoporosis treatment decision in patients with osteoarthritis: A multicenter comparative study of FRAX criteria and WHO criteria  ±èº¸¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:30~10:00 Angiogenesis using smart material  ±è¼º°ï(°­¸ª¿øÁÖ´ë Ä¡´ë ±¸°­¾Ç¾È¸é¿Ü°úÇÐ) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 10:00~10:30 Ãµ¿¬¹°À» ÀÌ¿ëÇÑ °ñ´Ù°øÁõ Ä¡·áÁ¦ °³¹ß  À¯ÁöÇý(KIST) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:00~11:40 Systemic and local fat in knee osteoarthritis.  Changhai Ding(Univ. of Tasmania, Australia) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:20~12:00 Management of systemic sclerosis -current status and future directions  Masataka Kuwana(Nippon Medical School, Japan) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 12:10~12:40 ICHOM standard set of outcomes that matter to patients suffering from inflammatory arthritis, explaining the goal of ICHOM, the methodology and how to apply this global development Mart  A.F.J van de Laar(University of Twente, the Netherlands) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:30~13:50 What¡¯s the choice after failure of first anti-TNF in RA?  Â÷ÈƼ®(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:50~14:10 To taper or not to taper biologics in RA?  ½É½Âö(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:10~14:30 Can we stop progression of structural damage in axial SpA?  ±è¿ë±æ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:30~14:50 Do we need to supplement vitamin D in autoimmune rheumatic diseases?  ±è±ÙÅÂ(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:30~15:50 New therapy in SLE: is the glass half-full or half-empty?  ¼­Ã¢Èñ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:50~16:10 Can we withdraw Immunosuppressants in patients with lupus nephritis in remission?  ¼ºÀ±°æ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:10~16:30 Do we still need biopsy to diagnose Sjögren¡¯s syndrome?  °û½Â±â(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:30~16:50 How can we better manage interstitial lung disease in systemic sclerosis?  ÀÌÀººÀ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:00~09:30 ÀÓ»óÁø·áÁöħ °³¹ß °³¿ä¿Í ±âȹ  ±èÀç±Ô(Áß¾ÓÀÇ´ë, ´ëÇÑÀÇÇÐȸ Á¤Ã¥ÀÌ»ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:30~09:50 Áø·áÁöħ °³¹ß °æÇè-GIOP¿Í ¿¹¹æÁ¢Á¾À» Áß½ÉÀ¸·Î  ÀüÂùÈ«(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:50~10:05 Áø·áÁöħ °³¹ß Çʿ伺-·ù¸¶Æ¼½º °üÀý¿°  ÀÌÁö¼ö(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 10:05~10:20 Ã༺ôÃß°üÀý¿°-°­Á÷ôÃß¿° Ä¡·á±Ç°í °³¹ß  ¹éÇÑÁÖ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 13:30~14:00 Is it possible to prevent RA?  ÀÌ»óÀÏ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:00~14:30 The cellular and molecular mechanisms in cartilage degeneration  Çѽ¿ì(°æºÏÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:30~15:00 CAR-T cells beyond cancer: A new therapy for autoimmune diseases?  Á¤ÁØÈ£(¼­¿ïÀÇ´ë »ýÈ­Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 15:30~16:00 Epigenetic control of immune cells.  ±è¶ô±Õ(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í°úÇкÎ) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:00~16:30 Follicular helper T cell.  ÃÖÀ±¼ö(¼­¿ïÀÇ´ë ÀÇ°úÇаú) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:30~17:00 Chronic/persistent infection and autoimmune diseases  ÃÖ¿µ´Ô(¼­¿ïÄ¡Àü¿ø ±¸°­¹Ì»ý¹°Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:30~13:50 ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌâÈÆ(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:50~14:10 °­Á÷ôÃß¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌ»ó¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:10~14:30 °í½ÄÀû ÇÕ¼º Ç×·ù¸¶Æ¼½ºÁ¦Á¦(csDMARDs) ¾Ë¾Æº¸±â  ±èÇö¼÷(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:30~14:50 ·ù¸¶Æ¼½º ÁúȯÀÇ Ç¥ÀûÄ¡·áÁ¦.  È«½ÂÀç(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 4Â÷»ê¾÷Çõ¸í°ú ³ëÈ­¿¬±¸ÀÇ ¹Ì·¡ (ÀüºÏÀÇ´ë »ýÈ­Çб³½Ç ±èÁ¾¼® ±³¼ö) / °¨¼ºÀ¸·Î ½Î¿ö¶ó -º´¿ø°æ¿µ(¹éâÈñ) : 2018-11-17
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø ´ëÀüÁö¿ª¾Ï¼¾ÅÍ È¯ÀÚ¿ì¼±ÀÇ °íÇ°°Ý ¾ÏÁø·á ½ÉÆ÷Áö¾ö : ´ÙÇÐÁ¦ ÅëÇÕÁø·á : 2018-11-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 124 2024-05-28
20896 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 208 2024-05-28
20895 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 163 2024-05-28
20894 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 71 2024-05-28
20893 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 91 2024-05-28
20892 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 52 2024-05-28
20891 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 83 2024-05-28
20890 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 183 2024-05-27
20889 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 118 2024-05-27
20888 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 250 2024-05-27
20887 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 118 2024-05-27
20886 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 57 2024-05-27
20885 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 57 2024-05-27
20884 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 98 2024-05-27
20883 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 92 2024-05-27
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷